<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Microbiol.</journal-id>
<journal-title>Frontiers in Microbiology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Microbiol.</abbrev-journal-title>
<issn pub-type="epub">1664-302X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fmicb.2024.1497377</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Microbiology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Fourier transform infrared spectroscopy for <italic>Streptococcus pneumoniae</italic> capsular serotype classification in pediatric patients with invasive infections</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes"><name><surname>Vasconcelos</surname> <given-names>Tha&#x00ED;s Muniz</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="author-notes" rid="fn0001"><sup>&#x2020;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/2833907/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes"><name><surname>Rodrigues</surname> <given-names>Luiza Souza</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="author-notes" rid="fn0001"><sup>&#x2020;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/842815/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
</contrib>
<contrib contrib-type="author"><name><surname>Krul</surname> <given-names>Damaris</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/2869594/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author"><name><surname>Barbosa</surname> <given-names>Sabrina da Concei&#x00E7;&#x00E3;o</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author"><name><surname>Siqueira</surname> <given-names>Adriele Celine</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/2895073/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author"><name><surname>Almeida</surname> <given-names>Samanta Cristine Grassi</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author"><name><surname>Pacheco Souza</surname> <given-names>Ana Paula de Oliveira</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author"><name><surname>Pillonetto</surname> <given-names>Marcelo</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author"><name><surname>Oliveira</surname> <given-names>Rodrigo</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/2845260/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author"><name><surname>Moonen</surname> <given-names>Carolyn Gertruda Josephina</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author"><name><surname>Siebra</surname> <given-names>Christian de Alencar</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/2857731/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes"><name><surname>Dalla-Costa</surname> <given-names>Libera Maria</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="c001"><sup>&#x002A;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/385329/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Faculdades Pequeno Pr&#x00ED;ncipe</institution>, <addr-line>Curitiba, Paran&#x00E1;</addr-line>, <country>Brazil</country></aff>
<aff id="aff2"><sup>2</sup><institution>Instituto de Pesquisa Pel&#x00E9; Pequeno Pr&#x00ED;ncipe</institution>, <addr-line>Curitiba, Paran&#x00E1;</addr-line>, <country>Brazil</country></aff>
<aff id="aff3"><sup>3</sup><institution>Laborat&#x00F3;rio Central do Estado do Paran&#x00E1; (LACEN/PR)</institution>, <addr-line>S&#x00E3;o Jos&#x00E9; dos Pinhais</addr-line>, <country>Brazil</country></aff>
<aff id="aff4"><sup>4</sup><institution>Instituto Adolfo Lutz (IAL)</institution>, <addr-line>S&#x00E3;o Paulo</addr-line>, <country>Brazil</country></aff>
<aff id="aff5"><sup>5</sup><institution>Hospital Pequeno Pr&#x00ED;ncipe (HPP)</institution>, <addr-line>Curitiba, Paran&#x00E1;</addr-line>, <country>Brazil</country></aff>
<aff id="aff6"><sup>6</sup><institution>Bruker Daltonics GmbH &#x0026; Co. KG</institution>, <addr-line>Bremen</addr-line>, <country>Germany</country></aff>
<author-notes>
<fn fn-type="edited-by" id="fn0002">
<p>Edited by: Leonard Peruski, Wadsworth Center, United States</p>
</fn>
<fn fn-type="edited-by" id="fn0003">
<p>Reviewed by: Sam Manna, Murdoch Childrens Research Institute, Australia</p>
<p>Laura Maria Andrade De Oliveira, Federal University of Rio de Janeiro, Brazil</p>
</fn>
<corresp id="c001">&#x002A;Correspondence: Libera Maria Dalla-Costa, <email>lmdallacosta@gmail.com</email>; <email>libera.costa@professor.fpp.edu.br</email></corresp>
<fn fn-type="equal" id="fn0001">
<p><sup>&#x2020;</sup>These authors have contributed equally to this work and share first authorship</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>21</day>
<month>11</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>15</volume>
<elocation-id>1497377</elocation-id>
<history>
<date date-type="received">
<day>16</day>
<month>09</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>08</day>
<month>11</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2024 Vasconcelos, Rodrigues, Krul, Barbosa, Siqueira, Almeida, Pacheco Souza, Pillonetto, Oliveira, Moonen, Siebra and Dalla-Costa.</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Vasconcelos, Rodrigues, Krul, Barbosa, Siqueira, Almeida, Pacheco Souza, Pillonetto, Oliveira, Moonen, Siebra and Dalla-Costa</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Invasive pneumococcal disease (IPD) is a major cause of morbidity and mortality worldwide, particularly in the pediatric population (children and infants), with high rates of hospitalization and death. This study aimed to create and validate a classifier for <italic>Streptococcus pneumoniae</italic> serotyping using Fourier-transform infrared (FT-IR) spectroscopy as a rapid alternative to the classical serotyping technique. In this study, a database comprising 76 clinical isolates, including 18 serotypes (predominantly serotypes 19A, 6C, and 3) of <italic>S. pneumoniae</italic> from pediatric patients with IPD, was tested at a tertiary pediatric hospital in southern Brazil during 2016&#x2013;2023. All isolates were previously serotyped using the Quellung reaction, and 843 FT-IR spectra were obtained to create a classification model using artificial neural network (ANN) machine learning. After the creation of this classifier, internal validation was performed using 384 spectra as the training dataset and 459 as the testing dataset, resulting in a predictive accuracy of 98% for serotypes 19A, 6, 3, 14, 18C, 22F, 23A, 23B, 33F, 35B, and 9N. In this dataset, serotypes 10A/16F, 15ABC, and 7CF could not be differentiated and were, therefore, grouped as labels. FT-IR is a promising, rapid, and low-cost method for the phenotypic classification of <italic>S. pneumoniae</italic> capsular serotypes. This methodology has significant implications for clinical and epidemiological practice, improving patient management, monitoring infection trends, and developing new vaccines.</p>
</abstract>
<kwd-group>
<kwd>
<italic>Streptococcus pneumoniae</italic>
</kwd>
<kwd>FT-IR spectroscopy</kwd>
<kwd>invasive pneumococcal disease</kwd>
<kwd>serotypes</kwd>
<kwd>pediatrics</kwd>
</kwd-group>
<counts>
<fig-count count="4"/>
<table-count count="1"/>
<equation-count count="0"/>
<ref-count count="36"/>
<page-count count="9"/>
<word-count count="5687"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Infectious Agents and Disease</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="sec1">
<label>1</label>
<title>Introduction</title>
<p><italic>Streptococcus pneumoniae</italic> colonizes the mucosal surfaces of the human upper respiratory tract, causing opportunistic, non-invasive, and invasive infections. Invasive pneumococcal disease (IPD) is a severe condition with high morbidity and mortality rates worldwide, notably affecting children under 5&#x2009;years of age (<xref ref-type="bibr" rid="ref34">Weiser et al., 2018</xref>). Vaccination is the most effective way to protect the general population from IPD (<xref ref-type="bibr" rid="ref19">Lages et al., 2020</xref>). There are differences in the distribution of pneumococcal serotypes among patients with IPD worldwide (<xref ref-type="bibr" rid="ref29">Silva-Costa et al., 2018</xref>). To date, 106 different capsular serotypes have been described and categorized (<xref ref-type="bibr" rid="ref15">Ganaie et al., 2020</xref>; <xref ref-type="bibr" rid="ref14">Ganaie et al., 2023b</xref>; <xref ref-type="bibr" rid="ref12">Ganaie et al., 2021</xref>; <xref ref-type="bibr" rid="ref13">Ganaie et al., 2023a</xref>; <xref ref-type="bibr" rid="ref21">Manna et al., 2024</xref>). However, only a few pneumococcal serotypes cause the vast majority of IPD cases worldwide, and different vaccines have been developed to target these prevalent serotypes (<xref ref-type="bibr" rid="ref15">Ganaie et al., 2020</xref>; <xref ref-type="bibr" rid="ref27">Qian et al., 2021</xref>). The first vaccine developed to control pneumococcal infections, the 23-valent pneumococcal polysaccharide, was introduced in 1983. However, due to the increase in penicillin-resistant pneumococci and also the observation that non-conjugate vaccines produced unsatisfactory results in children under 2&#x2009;years of age, the first pneumococcal conjugate vaccine (PCV), including seven pneumococcal serotypes (PCV7, serotypes 4, 6B, 9&#x2009;V, 14, 18C, 19F, and 23F), was developed and authorized for use in children in the USA in 2000 (<xref ref-type="bibr" rid="ref26">Rappuoli et al., 2019</xref>; <xref ref-type="bibr" rid="ref17">Jarovsky and Berezin, 2023</xref>). Two new second-generation conjugate vaccines with additional serotypes, PCV10 (additional serotypes 1, 5, and 7F) and PCV13 (additional serotypes 3, 6A, and 19A), were licensed based on their non-inferior immunogenicity to PCV7 (<xref ref-type="bibr" rid="ref17">Jarovsky and Berezin, 2023</xref>). Following the worldwide use of PCVs, the emergence of IPD due to non-vaccine serotypes and the development of new vaccines with a higher valency has emerged: PCV15, which adds serotypes 22F and 33F, has been approved for use in children and adults, and the PCV20 vaccine, which covers five more serotypes compared to PCV15 (8, 10A, 11A, 12F, and 15 B), was recently approved by the National Health Surveillance Agency (<italic>Ag&#x00EA;ncia Nacional de Vigil&#x00E2;ncia Sanit&#x00E1;ria</italic> - ANVISA) (<xref ref-type="bibr" rid="ref17">Jarovsky and Berezin, 2023</xref>; <xref ref-type="bibr" rid="ref18">Kfouri et al., 2023</xref>; <xref ref-type="bibr" rid="ref2">ANVISA AN de VS, 2023</xref>). The surveillance of circulating serotypes in the population is crucial for evaluating the impact of vaccination programs and understanding the distribution of circulating serotypes involved in IPDs (<xref ref-type="bibr" rid="ref3">Bardach et al., 2024</xref>). In the literature, two main approaches to investigating pneumococcal capsular types are characterized, these being serological and molecular methods (<xref ref-type="bibr" rid="ref1">Abdul Rahman et al., 2023</xref>). Molecular techniques include real-time PCR with amplification of the <italic>lytA</italic> gene, microarray using chips to detect and distinguish serotypes and whole genome sequencing (WGS) (<xref ref-type="bibr" rid="ref31">Swarthout et al., 2021</xref>; <xref ref-type="bibr" rid="ref1">Abdul Rahman et al., 2023</xref>; <xref ref-type="bibr" rid="ref11">Donkor, 2013</xref>; <xref ref-type="bibr" rid="ref33">Velusamy et al., 2020</xref>). The Quellung reaction, in which antisera are used and tested sequentially with pools of antisera until a positive reaction is observed in the identified pneumococcus strain, is considered the gold standard for identifying serotypes (<xref ref-type="bibr" rid="ref16">Habib et al., 2014</xref>; <xref ref-type="bibr" rid="ref23">Novais et al., 2019</xref>). The IR Biotyper<sup>&#x00AE;</sup> system, a Fourier transform infrared spectroscopy (FT-IR)-based method, shows promise for capsular typing (<xref ref-type="bibr" rid="ref23">Novais et al., 2019</xref>). IR spectroscopy provides a molecular fingerprint based on the absorption of infrared light (4,000&#x2013;500&#x2009;cm<sup>&#x2212;1</sup>) by carbohydrates, lipids, proteins, and lipopolysaccharides (<xref ref-type="bibr" rid="ref22">Muchaamba and Stephan, 2024</xref>). Specifically, the region of interest for capsular typing of <italic>Streptococcus pneumoniae</italic> focuses on carbohydrates, primarily characterized by absorbent properties (C-O stretching and O-H bending, 1,300&#x2013;800&#x2009;cm<sup>&#x2212;1</sup>). This method has demonstrated potential for serotyping various bacteria. FT-IR has been previously reported in the literature as an effective serotyping technique for <italic>S. pneumoniae</italic>, with comprehensive validation of the method (<xref ref-type="bibr" rid="ref7">Burckhardt et al., 2019</xref>; <xref ref-type="bibr" rid="ref24">Passaris et al., 2022</xref>). This study aimed to create a database and validate a local classifier for pneumococcal serotyping using FT-IR spectroscopy, on isolates exclusively from pediatric patients, as a quick and easy-to-perform alternative to the Quellung reaction.</p>
</sec>
<sec sec-type="materials|methods" id="sec2">
<label>2</label>
<title>Materials and methods</title>
<sec id="sec3">
<label>2.1</label>
<title>Study design</title>
<p>This was a retrospective longitudinal study of 76 clinical isolates of <italic>S. pneumoniae</italic> from pediatric patients diagnosed with IPD admitted between 2016 and 2023 to Hospital Pequeno Pr&#x00ED;ncipe, a 372-bed academic pediatric hospital in Curitiba, Paran&#x00E1;, southern Brazil. All isolates were stored in sheep blood with 20% glycerol at &#x2212;80&#x00B0;C (<xref ref-type="fig" rid="fig1">Figure 1A</xref>).</p>
<fig position="float" id="fig1">
<label>Figure 1</label>
<caption>
<p>Overview of practical sequential workflows of this study. <bold>(A)</bold> Steps involved in the selection and cryopreservation of clinical isolates included in the study. <bold>(B)</bold> Species identification using MALDI-TOF for the study isolates. <bold>(C)</bold> Workflow of IR Biotyper analysis. This figure was created by <ext-link xlink:href="http://Biorender.com" ext-link-type="uri">Biorender.com</ext-link>.</p>
</caption>
<graphic xlink:href="fmicb-15-1497377-g001.tif"/>
</fig>
</sec>
<sec id="sec4">
<label>2.2</label>
<title>Bacterial identification</title>
<p>Bacterial colonies were cultivated on 5% sheep blood Columbia agar base (CBAB 5%) (NEWPROV, Pinhais - PR, Brazil) at 37&#x00B0;C in an atmosphere of 5% CO<sub>2</sub> for 24&#x2009;h. Identification was carried out using matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) (Bruker Daltonics GmbH, Bremen, Germany) on a Microflex LT Bruker MALDI-TOF MS with flexControl v3.4 software (Bruker Daltonics GmbH, Bremen, Germany) (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Confirmation was achieved by standard methods (<xref ref-type="bibr" rid="ref35">WHO, 2011</xref>) species were identified by the susceptibility on the optochin test and on sodium deoxycholate (bile salt) solution.</p>
</sec>
<sec id="sec5">
<label>2.3</label>
<title><italic>Streptococcus pneumoniae</italic> serotyping</title>
<p>Serotyping was carried out at the Instituto Adolfo Lutz (IAL) of the National Reference Laboratory for Bacterial Meningitis and Invasive Pneumococcal Infections of the Brazilian Ministry of Health. <italic>S. pneumoniae</italic> was serotyped using pneumotest-latex agglutination and the Quellung reaction using antisera, both from Staten&#x2019;s Serum Institute (Copenhagen, Denmark) and according to the manufacturer&#x2019;s instructions. Non-typeable (NT) isolates identified by Quellung were also verified by the deduction of serotypes/serogroups using sequential multiplex PCR for 41 serospecificities, following the gene targets and protocols described by the Centers for Disease Control and Prevention, Atlanta, GA, United States (<xref ref-type="bibr" rid="ref8">Carvalho et al., 2010</xref>).</p>
</sec>
<sec id="sec6">
<label>2.4</label>
<title>Polysaccharide-based phenotypic typing with FT-IR spectroscopy</title>
<p>Polysaccharide-based phenotypic typing was conducted using the IR Biotyper<sup>&#x00AE;</sup> system (Bruker Daltonics, Germany), located at Laborat&#x00F3;rio Central do Estado do Paran&#x00E1; (LACEN/PR). The selected bacterial isolates were first cultured on CBAB 5% (NEWPROV, Pinhais - PR, Brazil) at 37&#x00B0;C in 5% CO<sub>2</sub> for 24&#x2009;h. The obtained bacterial colonies were subsequently cultured on MHF agar (Mueller Hinton agar +5% horse blood +20&#x2009;mg/L <italic>&#x03B2;</italic>-NAD, NEWPROV, Pinhais - PR, Brazil) and incubated at 37&#x00B0;C in 5% CO<sub>2</sub>. Suspensions of the bacterial isolates were prepared in IR Biotyper<sup>&#x00AE;</sup> suspension vials containing metal beads (IR Biotyper<sup>&#x00AE;</sup> kit, Bruker Daltonics GmbH, Bremen, Germany) according to the manufacturer&#x2019;s instructions. Portions of the culture colonies were removed using a 1&#x2009;&#x03BC;L disposable inoculation loop, and a homogeneous suspension was prepared in 50&#x2009;&#x03BC;L of 70% ethanol. After homogenization, 50&#x2009;&#x03BC;L of deionized water was added. The samples were then agitated at 1,350&#x2009;rpm for 5&#x2009;min (Thermomixer, Eppendorf, Hamburg, Germany). Subsequently, 15&#x2009;&#x03BC;L of each sample were dispensed in quintuplicate onto a reusable 96-well silicon IR Biotyper<sup>&#x00AE;</sup> plate (Bruker Daltonics GmbH, Bremen, Germany), with each spot serving as a technical replicate. For database generation, each isolate was sub-cultivated for 2 or 3&#x2009;days (biological replicates) to accommodate technical variability. Additionally, 10&#x2009;&#x03BC;L of the two standards, IRTS1 and IRTS2 (IR Biotyper<sup>&#x00AE;</sup> kit, Bruker Daltonics GmbH, Bremen, Germany), were included in duplicate on each plate per run (<xref ref-type="bibr" rid="ref6">Bruker, 2021</xref>; <xref ref-type="fig" rid="fig1">Figure 1C</xref>). One spot was left empty to measure the background after each spot. Spectra of poor quality, such as those with absorbance values outside the 0.4&#x2013;2.0 window, were excluded from analysis, aiming to include at least 12&#x2013;15 spectra of each isolate.</p>
</sec>
<sec id="sec7">
<label>2.5</label>
<title>FT-IR spectra</title>
<p>Spectra were acquired (transmission mode between wave numbers 4,000&#x2013;500&#x2009;cm<sup>&#x2212;1</sup>) and processed by OPUS software V.8.2.28 (Bruker Optics, Germany) on an IR Biotyper<sup>&#x00AE;</sup> with the corresponding IR Biotyper<sup>&#x00AE;</sup> software V4.0 (Bruker Daltonics) for data analysis. Spectral splicing was performed by default settings to the polysaccharide region of 1,300&#x2013;800&#x2009;cm<sup>&#x2212;1</sup>. For spectral distance visualization, dendrograms were created using the Euclidean distance as the exploration method with the UPGMA linkage type (average). Scatter plots in both 2D and 3D were visualized using dimension reduction techniques, namely Principal Component Analysis (PCA) and Linear Discriminant Analysis (LDA). To correct for technical variance, LDA was employed as a preprocessing step, capturing 95% of the variance with a maximum of 30 principal components, with isolate ID serving as the target group for the visualization of the 2D and 3D scatter plots. The isolates were labeled according to the corresponding Quellung reaction outputs to compare the results of the two techniques.</p>
</sec>
<sec id="sec8">
<label>2.6</label>
<title>Classifier creation with an artificial neural network (ANN) machine learning model to classify pneumococcal serotypes</title>
<p>Among the 76 <italic>S. pneumoniae</italic> isolates, 18 distinct serotypes were identified using Quellung serology (3, 6C, 7F, 7C, 9&#x2009;N, 10A, 16F, 14, 15A, 15B, 15C, 18C, 19A, 22F, 23A, 23B, 33F, and 35B). These same isolates were tested on the IR Biotyper<sup>&#x00AE;</sup> equipment to create a database for developing a classifier capable of distinguishing the different serotypes. All the spectra generated and stored in the newly created database were incorporated into the training data set. Additionally, two other machine-learning algorithms, a support vector machine with a radial basis function (RBF) kernel and another with a linear kernel, were evaluated. However, these algorithms failed to achieve a high classification accuracy (&#x003E;95%) during development and were subsequently discontinued. Subsequently, the IR Biotyper<sup>&#x00AE;</sup> software&#x2019;s machine learning algorithms were trained to process the spectra and build the classifier using an ANN, repeating this process over multiple cycles (300&#x2009;cycles), and producing a confusion matrix to evaluate the accuracy of the resulting classification model. It was determined that it was not feasible to differentiate between serotypes 15ABC, 10A/16F, and 7CF; these were amalgamated into a single group for future classification models. Ultimately, the classifiers&#x2019; accuracy was tested through an internal validation trial utilizing all the generated spectra, which were split into two sets: a training dataset and a testing/validation dataset containing 384 and 459 spectra, respectively. This process also produced a confusion matrix as an output file, which depicted the accuracy of the predicted outcomes in three colors (green, red, and yellow), confirming the reliability of the serotypes classified with our developed classifier.</p>
</sec>
</sec>
<sec sec-type="results" id="sec9">
<label>3</label>
<title>Results</title>
<sec id="sec10">
<label>3.1</label>
<title>Distribution of identified serotypes</title>
<p>Of the 76 isolates, 48 (63.2%) were isolated from blood, 15 (19.7%) from pleural fluid, 11 (14.5%) from cerebrospinal fluid, one (1.3%) from ascitic fluid and one (1.3%) from thoracentesis fluid samples. Eighteen distinct serotypes were identified, of which serotypes 19A, 6C, and 3 were the most prevalent (<xref ref-type="fig" rid="fig2">Figure 2</xref>). The three most prevalent serotypes [19A (gray), 6C (light pink) and 3 (green)] show the largest &#x201C;clouds&#x201D; in the 3D plot (<xref ref-type="fig" rid="fig2">Figure 2</xref>). In this plot, the first, second and third principal components are displayed, which already show some distinct clusters. For the further analysis, all 30 principal components were explored to see distinct clusters and therefore the possibility of distinguishing/differentiating all the serotypes measured. <xref ref-type="supplementary-material" rid="SM1">Supplementary Figure S1</xref> shows a deviation plot of the spectra generated by the readings of the three prevalent serotypes in our study, displaying their spectral differences. The IR Biotyper<sup>&#x00AE;</sup> spectra for serotypes 19A, 6C, and 3 were analyzed using a deviation plot, which presents the median spectra of each serotype group along with their respective standard deviations displayed as a shade. In this deviation plot, the spectral differences between serotypes 19A, 6C, and 3 are shown, indicating that these can be differentiated using FT-IR. With the use of machine learning algorithm, which is incorporated in the IR Biotyper<sup>&#x00AE;</sup> software, a classification model could be made. The purpose of a classifier is to evaluate spectra without the need of manual exploratory data analysis. This means that when a classification model is applied in the software (automatically triggered for pneumococci), it immediately predicts the outcome of any unknown measured spectrum such as the serotype. The created pneumococci serotype classifier can then be used in the future for automated serotype classification, during measurement of pneumococci isolates. Different serotypes can be observed in the dendrogram (<xref ref-type="supplementary-material" rid="SM2">Supplementary Figure S2</xref>), where the serotypes are represented in different colors on the right vertical axis. The cutoff value (8.216) of the dendrogram was an automatically calculated cutoff value (based on Simpson&#x2019;s diversity index &#x00D7; mean coherence), which was selected to visualize the different serogroups and observe the clustering of the samples individually. The program has a limitation on the number of spectra (up to 500 spectra) to generate the dendrogram. To generate <xref ref-type="supplementary-material" rid="SM2">Supplementary Figure S2</xref>, the &#x201C;average&#x201D; function was used, which means that the spectra (both technical and biological representatives) are presented as &#x201C;average spectra.&#x201D; In this model, serotypes 9&#x2009;N, 10A, 16F, 7C, and 7F are not distinguishable in the dendrogram, but this case does not create a problem in our classification model. For a dataset consisting of a total of 843 spectra obtained in the study, the use of a dendrogram to visualize clustering may not be recommended due to the complexity of visualizing hierarchical relationships. Dendrograms are effective for smaller datasets. An alternative to overcome this limitation is to use dimension reduction techniques, such as LDA. By applying LDA, the informative features of the spectra are retained, simplifying the data and revealing patterns that would otherwise cannot be seen in the dendrogram.</p>
<fig position="float" id="fig2">
<label>Figure 2</label>
<caption>
<p>Representation of IR Biotyper results as a 3D scatter plot (LDA with 30 PCs accounting for 97.8% of the variation) from 843 spectra.</p>
</caption>
<graphic xlink:href="fmicb-15-1497377-g002.tif"/>
</fig>
</sec>
<sec id="sec11">
<label>3.2</label>
<title>Classification and validation of pneumococcal serotypes</title>
<p>From the spectra obtained from 76 isolates representing 14 distinct serotypes (<xref ref-type="table" rid="tab1">Table 1</xref>), a classifier was developed using all available machine learning algorithms in the IR Biotyper<sup>&#x00AE;</sup> software. Among these algorithms, the Artificial Neural Network (ANN) machine learning demonstrated the highest possible accuracy. Upon creating the classifier, the confusion matrix immediately displayed the model&#x2019;s classification accuracy. However, with the initial classifier differentiating all 14 serotypes, the accuracy threshold of &#x003E;95% was not achieved due to misclassifications between serotypes 10A, 16F, 7C, 7F, 15A, 15B, and 15C, which was also visually evident in the 3D scatter plots from the LDA. For example, the confusion matrix showed that serotype 10A (actual class, vertical axis) was predicted as serotype 16F (predicted class, horizontal axis), indicating that these two serotypes could not be distinguished within this dataset. As a result, serotypes 10A and 16F were merged into a single label, 10A/16F, in the classifier. Similarly, serotypes 7C and 7F, as well as 15B and 15C, were combined. As a result, to create our final classifier, from the 76 isolates tested, 843 spectra were generated, classifying 11 distinct serotypes and three serogroups (<xref ref-type="table" rid="tab1">Table 1</xref>), achieving an accuracy of 100% after 300 training cycles of the ANN (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). The classifier was then ready for use, but before implementation, an internal validation was conducted to assess its robustness. Consequently, the entire dataset was partitioned into two groups: Group 1, the training set with &#x201C;reduced&#x201D; data, encompassed 384 spectra (<xref ref-type="fig" rid="fig3">Figure 3B</xref>); Group 2, used to test and validate the classifier, included 459 spectra (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Isolates in the training dataset displaying variance in their respective serotypes were selected. Following the 300-cycle training of the neural network, model using these two groups, an accuracy of 98% was achieved (<xref ref-type="fig" rid="fig4">Figure 4</xref>).</p>
<table-wrap position="float" id="tab1">
<label>Table 1</label>
<caption>
<p>Analysis includes <italic>Streptococcus pneumoniae</italic> isolates.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" valign="top">Serotypes</th>
<th align="center" valign="top">Number of isolates</th>
<th align="center" valign="top">Number of spectra</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" valign="top">19A</td>
<td align="center" valign="top">38</td>
<td align="center" valign="top">304</td>
</tr>
<tr>
<td align="center" valign="top">6C</td>
<td align="center" valign="top">11</td>
<td align="center" valign="top">143</td>
</tr>
<tr>
<td align="center" valign="top">15ABC</td>
<td align="center" valign="top">6</td>
<td align="center" valign="top">78</td>
</tr>
<tr>
<td align="center" valign="top">3</td>
<td align="center" valign="top">4</td>
<td align="center" valign="top">72</td>
</tr>
<tr>
<td align="center" valign="top">10A/16F</td>
<td align="center" valign="top">3</td>
<td align="center" valign="top">54</td>
</tr>
<tr>
<td align="center" valign="top">7CF</td>
<td align="center" valign="top">2</td>
<td align="center" valign="top">36</td>
</tr>
<tr>
<td align="center" valign="top">33F</td>
<td align="center" valign="top">2</td>
<td align="center" valign="top">26</td>
</tr>
<tr>
<td align="center" valign="top">23B</td>
<td align="center" valign="top">3</td>
<td align="center" valign="top">24</td>
</tr>
<tr>
<td align="center" valign="top">18C</td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">18</td>
</tr>
<tr>
<td align="center" valign="top">22F</td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">18</td>
</tr>
<tr>
<td align="center" valign="top">23A</td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">18</td>
</tr>
<tr>
<td align="center" valign="top">35B</td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">18</td>
</tr>
<tr>
<td align="center" valign="top">9&#x2009;N</td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">18</td>
</tr>
<tr>
<td align="center" valign="top">14</td>
<td align="center" valign="top">2</td>
<td align="center" valign="top">16</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>Groupings of serotypes into their respective classification groups include 10A with 16F; 7C with 7F; and 15A, 15B, and 15C.</p>
</table-wrap-foot>
</table-wrap>
<fig position="float" id="fig3">
<label>Figure 3</label>
<caption>
<p>Classification and validation of pneumococcal serotypes. <bold>(A)</bold> Confusion matrix demonstrating the classifier&#x2019;s creation from 843 spectra using ANN over 300&#x2009;cycles, achieving 100% accuracy. The vertical axis displays trained labels (actual class), and the horizontal axis shows predicted classes by the classifier model. <bold>(B)</bold> IR Biotyper result represented as a 3D scatter plot from the classifier creation training dataset, involving 384 spectra from 39 isolates representing all 18 serotypes (LDA with 30 PCs/97.7% variance). Colors and shapes differentiate serotypes and isolates, respectively. <bold>(C)</bold> IR Biotyper result represented as a 3D scatter plot from the classifier creation validation dataset, involving 459 spectra from 48 isolates representing all 18 serotypes (LDA with 30 PCs/98.2% variance). Colors and shapes differentiate serotypes and isolates, respectively.</p>
</caption>
<graphic xlink:href="fmicb-15-1497377-g003.tif"/>
</fig>
<fig position="float" id="fig4">
<label>Figure 4</label>
<caption>
<p>Confusion matrix for the internal validation of the classifier, showing 98% accuracy. The vertical axis displays trained labels (class recall&#x2009;=&#x2009;sensitivity), and the horizontal axis shows predicted classes (class precision&#x2009;=&#x2009;specificity), by the classifier model. Green for compatible spectra; Red for spectra crossings; Yellow for uncertain.</p>
</caption>
<graphic xlink:href="fmicb-15-1497377-g004.tif"/>
</fig>
</sec>
</sec>
<sec sec-type="discussion" id="sec12">
<label>4</label>
<title>Discussion</title>
<p>IPD is of particular concern in the pediatric population because of its associated high morbidity and mortality rates. The serological types of <italic>S. pneumoniae</italic> demonstrate different clinical and epidemiological characteristics, and their accurate identification is crucial for the proper management of the disease and formulation of vaccine strategies (<xref ref-type="bibr" rid="ref10">Croney et al., 2013</xref>; <xref ref-type="bibr" rid="ref32">Thadchanamoorthy and Dayasiri, 2021</xref>). In this study, we observed that serotypes 19A, 6C, and 3 were circulating in our hospital. Serotype 19A has been reported as one of the most common serotypes isolated from IPDs and is associated with a high mortality rate, especially in the pediatric population in various medical centers (<xref ref-type="bibr" rid="ref20">Lyu et al., 2024</xref>; <xref ref-type="bibr" rid="ref28">Shoji et al., 2018</xref>). In Brazil, the PCV10 vaccine was introduced into the childhood National Immunization Program in 2010 and is still available for administration to children up to 1&#x2009;year of age in the primary scheme of two doses (2 and 4&#x2009;months) plus a booster (12&#x2009;months) to complete the scheme (<xref ref-type="bibr" rid="ref5">Brasil, Minist&#x00E9;rio da Sa&#x00FA;de, 2023</xref>). However, the PCV10 vaccine does not cover serotypes 19A, 6C, and 3, which may explain the prevalence of isolates belonging to these serotypes recovered in our series. Data related to PCV10 vaccination coverage in the state of Paran&#x00E1; in 2023 were approximately 92,752% in the primary scheme doses and 82, 77% in the complete scheme with a booster dose. In 2023, the pneumonia and meningitis surveillance bulletin reported 345 serotype 19A isolates in Brazil, with 44.6% (<italic>n</italic>&#x2009;=&#x2009;154/345) identified in patients aged &#x003C;5&#x2009;years (<xref ref-type="bibr" rid="ref30">SIREVA, 2023</xref>). Notably, serotype 3 remains highly prevalent, even in countries that have incorporated high-valence PCVs, including serotype 3 in their formulation (PCV13, PCV15, and PCV20) (<xref ref-type="bibr" rid="ref4">Bertran et al., 2024</xref>). This prevalence is attributed to the capsule synthesis pathway, where modifications in glycosidic bonds lead to thicker capsules, forming mucoid colonies. Furthermore, <italic>S. pneumoniae</italic> serotype 3 produces and releases capsules during cell growth, which inhibits antibody opsonization. Clinically, this can result in vaccination failures, resistance to phagocytosis, and subsequent respiratory infections (<xref ref-type="bibr" rid="ref9">Choi et al., 2016</xref>; <xref ref-type="bibr" rid="ref25">Paton and Trappetti, 2019</xref>; <xref ref-type="bibr" rid="ref36">Yang et al., 2021</xref>). The Quellung reaction, performed at the reference laboratory IAL in Brazil, remains the gold standard for serological typing of <italic>S. pneumoniae</italic> strains, despite its limitations such as the variety, quantity, and cost of antisera required, typically restricted to reference centers with the necessary expertise. Conversely, the FT-IR serotyping method offers a promising alternative, significantly reducing the time to obtain results compared to traditional methods and at a lower cost. The IR Biotyper<sup>&#x00AE;</sup> software facilitates immediate, real-time classification of 34 distinct serotypes of <italic>S. pneumoniae</italic> using the Bruker Classifier included with the IR Biotyper<sup>&#x00AE;</sup> 4.0 software However, it is important to note that this classification model was developed by manufacturers using isolates grown on Columbia blood agar with a smear protocol after UV inactivation (<xref ref-type="bibr" rid="ref24">Passaris et al., 2022</xref>). In this study, we were use IR Biotyper<sup>&#x00AE;</sup> suspension vials for sample preparations. In the context of this project, a custom classifier was developed specifically to predict serotypes in real-time in local circulating serotype analysis of pneumococcal samples in Paran&#x00E1;, Brazil. This classification model, with ANN machine learning integrated into the IR Biotyper<sup>&#x00AE;</sup> software, achieved an accuracy is 98%, based on the training dataset. Furthermore, the IR Biotyper<sup>&#x00AE;</sup> software allows users to retrain the classifier by modifying its training dataset, providing flexibility to update and improve its predictive model, thus increasing its robustness. In summary, the IR Biotyper<sup>&#x00AE;</sup> is proving to be a promising tool for the phenotypic classification of <italic>S. pneumoniae</italic> serotypes. Validation of this technology will make it possible to monitor circulating serotypes in cases of IPD with a quick turnaround time and low cost, with a positive impact on clinical and epidemiological aspects, vaccine production, and patient management. In addition, it allows for the expansion of this technology to other medical and research centers that are not restricted to reference laboratories. One limitation is that, for some of the serotypes we found, we only had one isolate. According to the IR Biotyper<sup>&#x00AE;</sup> software manual, it is recommended to have several spectra per isolate from independent cultivations. For this reason, we increased the number of spectra, including technical and biological variations, for classifier training and internal validation to classify them accurately. In the future, it is necessary to include more of these less prevalent isolates to re-train the classifier model and increase the sensitivity and specificity of the model for these serotypes. However, this did not affect our study because these were not the most prevalent serotypes in our setting. For the bacterial suspension protocol proposed by the manufacturer, a high biomass is required in this suspension, which can be a challenge for <italic>S. pneumoniae</italic>. It is also important to note that this classification model should be tested with an external validation set, which is a recommended step before implementing it in routine diagnostic use. Considering that this is a phenotypic test, it is important to consider and include precautions that must be taken to obtain reproducible results, such as following the manufacturer&#x2019;s culture medium respecting the same composition and the recommended incubation temperature.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="sec13">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/<xref ref-type="sec" rid="sec18">Supplementary material</xref>, further inquiries can be directed to the corresponding author.</p>
</sec>
<sec sec-type="author-contributions" id="sec14">
<title>Author contributions</title>
<p>TV: Formal analysis, Methodology, Validation, Writing &#x2013; original draft, Writing &#x2013; review &#x0026; editing. LR: Conceptualization, Formal analysis, Funding acquisition, Methodology, Writing &#x2013; original draft, Writing &#x2013; review &#x0026; editing, Validation. DK: Methodology, Validation, Writing &#x2013; review &#x0026; editing. SB: Methodology, Writing &#x2013; review &#x0026; editing. AS: Methodology, Writing &#x2013; review &#x0026; editing. SA: Data curation, Methodology, Writing &#x2013; review &#x0026; editing. AP: Writing &#x2013; review &#x0026; editing. MP: Writing &#x2013; review &#x0026; editing. RO: Data curation, Formal analysis, Validation, Writing &#x2013; review &#x0026; editing. CM: Data curation, Formal analysis, Validation, Writing &#x2013; review &#x0026; editing. CS: Methodology, Validation, Writing &#x2013; review &#x0026; editing. LD-C: Conceptualization, Funding acquisition, Project administration, Supervision, Writing &#x2013; review &#x0026; editing.</p>
</sec>
<sec sec-type="funding-information" id="sec15">
<title>Funding</title>
<p>The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This study was financed in part by the Coordena&#x00E7;&#x00E3;o de Aperfei&#x00E7;oamento de Pessoal de N&#x00ED;vel Superior Brasil (CAPES) &#x2013; Finance Code 001 and the Grant Pfizer Project (Pfizer Global Medical Grants - Request Number - # 76515163).</p>
</sec>
<ack>
<p>IR-Biotyper assays were conducted using IR Biotyper<sup>&#x00AE;</sup> system (Bruker Daltonics, Germany) at Laborat&#x00F3;rio Central do Estado do Paran&#x00E1; (LACEN/PR). Serotyping was performed at the Center for Meningitis, Pneumonia, and Pneumococcal Infections of the Bacteriology Center of the Adolfo Lutz Institute (IAL) in S&#x00E3;o Paulo, SP, Brazil.</p>
</ack>
<sec sec-type="COI-statement" id="sec16">
<title>Conflict of interest</title>
<p>RO and CM are employees of Bruker Daltonics GmbH and Co. KG, Germany.</p>
<p>The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="sec17">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec sec-type="supplementary-material" id="sec18">
<title>Supplementary material</title>
<p>The Supplementary material for this article can be found online at: <ext-link xlink:href="https://www.frontiersin.org/articles/10.3389/fmicb.2024.1497377/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fmicb.2024.1497377/full#supplementary-material</ext-link></p>
<supplementary-material xlink:href="Image_1.tif" id="SM1" mimetype="image/tiff" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Image_2.tif" id="SM2" mimetype="image/tiff" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="ref1">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abdul Rahman</surname> <given-names>N. A.</given-names></name> <name><surname>Mohd Desa</surname> <given-names>M. N.</given-names></name> <name><surname>Masri</surname> <given-names>S. N.</given-names></name> <name><surname>Taib</surname> <given-names>N. M.</given-names></name> <name><surname>Sulaiman</surname> <given-names>N.</given-names></name> <name><surname>Hazman</surname> <given-names>H.</given-names></name> <etal/></person-group>. (<year>2023</year>). <article-title>The molecular approaches and challenges of <italic>Streptococcus pneumoniae</italic> serotyping for epidemiological surveillance in the vaccine era</article-title>. <source>Polish J. Microbiol.</source> <volume>72</volume>, <fpage>103</fpage>&#x2013;<lpage>115</lpage>. doi: <pub-id pub-id-type="doi">10.33073/pjm-2023-023</pub-id>, PMID: <pub-id pub-id-type="pmid">37314355</pub-id></citation>
</ref>
<ref id="ref2">
<citation citation-type="other"><person-group person-group-type="author">
<collab id="coll1">ANVISA AN de VS</collab>
</person-group>. <source>Prevenar<sup>&#x00AE;</sup> 20 (Vacina pneumoc&#x00F3;cica 20-valente conjugada): novo registro [Internet]</source>. (<year>2023</year>). Available at: <ext-link xlink:href="https://www.gov.br/anvisa/pt-br/assuntos/medicamentos/novos-medicamentos-e-indicacoes/prevenar-r-20-vacina-pneumococica-20-valente-conjugada-novo-registro" ext-link-type="uri">https://www.gov.br/anvisa/pt-br/assuntos/medicamentos/novos-medicamentos-e-indicacoes/prevenar-r-20-vacina-pneumococica-20-valente-conjugada-novo-registro</ext-link></citation>
</ref>
<ref id="ref3">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bardach</surname> <given-names>A.</given-names></name> <name><surname>Ruvinsky</surname> <given-names>S.</given-names></name> <name><surname>Palermo</surname> <given-names>M. C.</given-names></name> <name><surname>Alconada</surname> <given-names>T.</given-names></name> <name><surname>Sandoval</surname> <given-names>M. M.</given-names></name> <name><surname>Brizuela</surname> <given-names>M. E.</given-names></name> <etal/></person-group>. (<year>2024</year>). <article-title>Invasive pneumococcal disease in Latin America and the Caribbean: serotype distribution, disease burden, and impact of vaccination. A systematic review and meta-analysis</article-title>. <source>PLoS One</source> <volume>19</volume>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0304978</pub-id></citation>
</ref>
<ref id="ref4">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bertran</surname> <given-names>M.</given-names></name> <name><surname>D&#x2019;Aeth</surname> <given-names>J. C.</given-names></name> <name><surname>Abdullahi</surname> <given-names>F.</given-names></name> <name><surname>Eletu</surname> <given-names>S.</given-names></name> <name><surname>Andrews</surname> <given-names>N. J.</given-names></name> <name><surname>Ramsay</surname> <given-names>M. E.</given-names></name> <etal/></person-group>. (<year>2024</year>). <article-title>Invasive pneumococcal disease 3 years after introduction of a reduced 1&#x2009;+&#x2009;1 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective national observational surveillance study</article-title>. <source>Lancet Infect. Dis.</source> <volume>24</volume>, <fpage>546</fpage>&#x2013;<lpage>556</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1473-3099(23)00706-5</pub-id>, PMID: <pub-id pub-id-type="pmid">38310905</pub-id></citation>
</ref>
<ref id="ref5">
<citation citation-type="book"><person-group person-group-type="author">
<collab id="coll2">Brasil, Minist&#x00E9;rio da Sa&#x00FA;de</collab>
</person-group> (<year>2023</year>). <source>Calend&#x00E1;rio Nacional de Vacina&#x00E7;&#x00E3;o da Crian&#x00E7;a</source>. <publisher-loc>Brasil</publisher-loc>:<publisher-name>Minist&#x00E9;rio da Sa&#x00FA;de</publisher-name>. Available at: <ext-link xlink:href="https://www.gov.br/saude/pt-br/vacinacao/calendario" ext-link-type="uri">https://www.gov.br/saude/pt-br/vacinacao/calendario</ext-link> (Accessed November 13, 2024).</citation>
</ref>
<ref id="ref6">
<citation citation-type="other"><person-group person-group-type="author">
<collab id="coll3">Bruker</collab>
</person-group>. <source>IR Biotyper user manual</source>. (<year>2021</year>) REF 1845471, May 2022. Doc. no. 5025119 Revision F.</citation>
</ref>
<ref id="ref7">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burckhardt</surname> <given-names>I.</given-names></name> <name><surname>Sebastian</surname> <given-names>K.</given-names></name> <name><surname>Mauder</surname> <given-names>N.</given-names></name> <name><surname>Kostrzewa</surname> <given-names>M.</given-names></name> <name><surname>Burckhardt</surname> <given-names>F.</given-names></name> <name><surname>Zimmermann</surname> <given-names>S.</given-names></name></person-group> (<year>2019</year>). <article-title>Analysis of <italic>Streptococcus pneumoniae</italic> using Fourier-transformed infrared spectroscopy allows prediction of capsular serotype</article-title>. <source>Eur. J. Clin. Microbiol. Infect. Dis.</source> <volume>38</volume>, <fpage>1883</fpage>&#x2013;<lpage>1890</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10096-019-03622-y</pub-id>, PMID: <pub-id pub-id-type="pmid">31286288</pub-id></citation>
</ref>
<ref id="ref8">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carvalho</surname> <given-names>M. D. G.</given-names></name> <name><surname>Pimenta</surname> <given-names>F. C.</given-names></name> <name><surname>Jackson</surname> <given-names>D.</given-names></name> <name><surname>Roundtree</surname> <given-names>A.</given-names></name> <name><surname>Ahmad</surname> <given-names>Y.</given-names></name> <name><surname>Millar</surname> <given-names>E. V.</given-names></name> <etal/></person-group>. (<year>2010</year>). <article-title>Revisiting pneumococcal carriage by use of broth enrichment and PCR techniques for enhanced detection of carriage and serotypes</article-title>. <source>J. Clin. Microbiol.</source> <volume>48</volume>, <fpage>1611</fpage>&#x2013;<lpage>1618</lpage>. doi: <pub-id pub-id-type="doi">10.1128/JCM.02243-09</pub-id>, PMID: <pub-id pub-id-type="pmid">20220175</pub-id></citation>
</ref>
<ref id="ref9">
<citation citation-type="other"><person-group person-group-type="author"><name><surname>Choi</surname> <given-names>E. H.</given-names></name> <name><surname>Zhang</surname> <given-names>F.</given-names></name> <name><surname>Lu</surname> <given-names>Y.</given-names></name> <name><surname>Malley</surname> <given-names>R.</given-names></name></person-group> (<year>2016</year>). <article-title>Capsular polysaccharide (CPS) release by serotype 3 pneumococcal strains reduces the protective effect of anti-type 3 CPS antibodies</article-title> <volume>23</volume>, <fpage>162</fpage>&#x2013;<lpage>167</lpage>. doi: <pub-id pub-id-type="doi">10.1128/CVI.00591-15</pub-id></citation>
</ref>
<ref id="ref10">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Croney</surname> <given-names>C. M.</given-names></name> <name><surname>Nahm</surname> <given-names>M. H.</given-names></name> <name><surname>Juhn</surname> <given-names>S. K.</given-names></name> <name><surname>Briles</surname> <given-names>D. E.</given-names></name> <name><surname>Crain</surname> <given-names>M. J.</given-names></name></person-group> (<year>2013</year>). <article-title>Invasive and noninvasive <italic>Streptococcus pneumoniae</italic> capsule and surface protein diversity following the use of a conjugate vaccine</article-title>. <source>Clin. Vaccine Immunol.</source> <volume>20</volume>, <fpage>1711</fpage>&#x2013;<lpage>1718</lpage>. doi: <pub-id pub-id-type="doi">10.1128/CVI.00381-13</pub-id>, PMID: <pub-id pub-id-type="pmid">24006139</pub-id></citation>
</ref>
<ref id="ref11">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Donkor</surname> <given-names>E. S.</given-names></name>
</person-group> (<year>2013</year>). <article-title>Molecular typing of the pneumococcus and its application in epidemiology in sub-Saharan Africa</article-title>. <source>Front. Cell. Infect. Microbiol.</source> <volume>3</volume>:<fpage>12</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fcimb.2013.00012</pub-id></citation>
</ref>
<ref id="ref12">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ganaie</surname> <given-names>F.</given-names></name> <name><surname>Maruhn</surname> <given-names>K.</given-names></name> <name><surname>Li</surname> <given-names>C.</given-names></name> <name><surname>Porambo</surname> <given-names>R. J.</given-names></name> <name><surname>Elverdal</surname> <given-names>P. L.</given-names></name> <name><surname>Abeygunwardana</surname> <given-names>C.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>Structural, genetic, and serological elucidation of <italic>Streptococcus pneumoniae</italic> serogroup 24 serotypes: discovery of a new serotype, 24C, with a variable capsule structure</article-title>. <source>J. Clin. Microbiol.</source> <volume>59</volume>:<fpage>e0054021</fpage>. doi: <pub-id pub-id-type="doi">10.1128/JCM.00540-21</pub-id>, PMID: <pub-id pub-id-type="pmid">33883183</pub-id></citation>
</ref>
<ref id="ref13">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ganaie</surname> <given-names>F. A.</given-names></name> <name><surname>Saad</surname> <given-names>J. S.</given-names></name> <name><surname>Lo</surname> <given-names>S. W.</given-names></name> <name><surname>McGee</surname> <given-names>L.</given-names></name> <name><surname>Bentley</surname> <given-names>S. D.</given-names></name> <name><surname>van Tonder</surname> <given-names>A. J.</given-names></name> <etal/></person-group>. (<year>2023a</year>). <article-title>Discovery and characterization of pneumococcal serogroup 36 capsule subtypes, serotypes 36A and 36B</article-title>. <source>J. Clin. Microbiol.</source> <volume>61</volume>:<fpage>e0002423</fpage>. doi: <pub-id pub-id-type="doi">10.1128/jcm.00024-23</pub-id>, PMID: <pub-id pub-id-type="pmid">36971549</pub-id></citation>
</ref>
<ref id="ref14">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ganaie</surname> <given-names>F. A.</given-names></name> <name><surname>Saad</surname> <given-names>J. S.</given-names></name> <name><surname>Lo</surname> <given-names>S. W.</given-names></name> <name><surname>McGee</surname> <given-names>L.</given-names></name> <name><surname>van Tonder</surname> <given-names>A. J.</given-names></name> <name><surname>Hawkins</surname> <given-names>P. A.</given-names></name> <etal/></person-group>. (<year>2023b</year>). <article-title>Novel pneumococcal capsule type 33E results from the inactivation of glycosyltransferase WciE in vaccine type 33F</article-title>. <source>J. Biol. Chem.</source> <volume>299</volume>:<fpage>105085</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jbc.2023.105085</pub-id>, PMID: <pub-id pub-id-type="pmid">37495106</pub-id></citation>
</ref>
<ref id="ref15">
<citation citation-type="other"><person-group person-group-type="author"><name><surname>Ganaie</surname> <given-names>F.</given-names></name> <name><surname>Saad</surname> <given-names>J. S.</given-names></name> <name><surname>Mcgee</surname> <given-names>L.</given-names></name> <name><surname>Van</surname> <given-names>T. A. J.</given-names></name> <name><surname>Bentley</surname> <given-names>S. D.</given-names></name> <name><surname>Lo</surname> <given-names>S. W.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>A new pneumococcal capsule type, 10D, is the 100th serotype and has a large cps fragment from an oral <italic>Streptococcus</italic></article-title> <volume>11</volume>:<fpage>e00937-20</fpage>. doi: <pub-id pub-id-type="doi">10.1128/mBio.00937-20</pub-id></citation>
</ref>
<ref id="ref16">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Habib</surname> <given-names>M.</given-names></name> <name><surname>Porter</surname> <given-names>B. D.</given-names></name> <name><surname>Satzke</surname> <given-names>C.</given-names></name></person-group> (<year>2014</year>). <article-title>Capsular serotyping of <italic>Streptococcus pneumoniae</italic> using the quellung reaction</article-title>. <source>J. Vis. Exp.</source> <volume>84</volume>, <fpage>1</fpage>&#x2013;<lpage>4</lpage>. doi: <pub-id pub-id-type="doi">10.3791/51208</pub-id></citation>
</ref>
<ref id="ref17">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jarovsky</surname> <given-names>D.</given-names></name> <name><surname>Berezin</surname> <given-names>E. N.</given-names></name></person-group> (<year>2023</year>). <article-title>Impact of PCV10 on pediatric pneumococcal disease burden in Brazil: time for new recommendations?</article-title> <source>J. Pediatr.</source> <volume>99</volume>, <fpage>S46</fpage>&#x2013;<lpage>S56</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jped.2022.11.003</pub-id>, PMID: <pub-id pub-id-type="pmid">36495946</pub-id></citation>
</ref>
<ref id="ref18">
<citation citation-type="other"><person-group person-group-type="author"><name><surname>Kfouri</surname> <given-names>R. A.</given-names></name> <name><surname>Brandileone</surname> <given-names>M.</given-names></name> <name><surname>Cristina</surname> <given-names>C.</given-names></name> <name><surname>Richtmann</surname> <given-names>R.</given-names></name> <name><surname>Gilio</surname> <given-names>A. E. S. P.</given-names></name></person-group> (<year>2023</year>). <article-title>Chronic medical conditions associated with invasive pneumococcal diseases in inpatients in teaching ~ o Paulo city: estimating antimicrobial hospitals in S a susceptibility and serotype-coverage of pneumococcal vaccines</article-title> <volume>27</volume>, <fpage>102746</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bjid.2023.102746</pub-id>, PMID: <pub-id pub-id-type="pmid">36758625</pub-id></citation>
</ref>
<ref id="ref19">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lages</surname> <given-names>P. M.</given-names></name> <name><surname>Carlesse</surname> <given-names>F.</given-names></name> <name><surname>Boettger</surname> <given-names>B. C.</given-names></name> <name><surname>Pignatari</surname> <given-names>A. C. C.</given-names></name> <name><surname>Petrilli</surname> <given-names>A. S.</given-names></name> <name><surname>de Moraes-Pinto</surname> <given-names>M. I.</given-names></name></person-group> (<year>2020</year>). <article-title>Invasive pneumococcal disease in children with cancer: incidence density, risk factors and isolated serotypes</article-title>. <source>Braz. J. Infect. Dis.</source> <volume>24</volume>, <fpage>489</fpage>&#x2013;<lpage>496</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bjid.2020.09.003</pub-id>, PMID: <pub-id pub-id-type="pmid">33164827</pub-id></citation>
</ref>
<ref id="ref20">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lyu</surname> <given-names>S.</given-names></name> <name><surname>Shi</surname> <given-names>W.</given-names></name> <name><surname>Dong</surname> <given-names>F.</given-names></name> <name><surname>Xu</surname> <given-names>B. P.</given-names></name> <name><surname>Liu</surname> <given-names>G.</given-names></name> <name><surname>Wang</surname> <given-names>Q.</given-names></name> <etal/></person-group>. (<year>2024</year>). <article-title>Serotype distribution and antimicrobial resistance of pediatric <italic>Streptococcus pneumoniae</italic> isolated from inpatients and outpatients at Beijing Children&#x2019;s hospital</article-title>. <source>Braz. J. Infect. Dis.</source> <volume>28</volume>:<fpage>103734</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bjid.2024.103734</pub-id>, PMID: <pub-id pub-id-type="pmid">38471654</pub-id></citation>
</ref>
<ref id="ref21">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Manna</surname> <given-names>S.</given-names></name> <name><surname>Werren</surname> <given-names>J. P.</given-names></name> <name><surname>Ortika</surname> <given-names>B. D.</given-names></name> <name><surname>Bellich</surname> <given-names>B.</given-names></name> <name><surname>Pell</surname> <given-names>C. L.</given-names></name> <name><surname>Nikolaou</surname> <given-names>E.</given-names></name> <etal/></person-group>. (<year>2024</year>). <article-title><italic>Streptococcus pneumoniae</italic> serotype 33G: genetic, serological, and structural analysis of a new capsule type</article-title>. <source>Microbiol. Spectr.</source> <volume>12</volume>:<fpage>e0357923</fpage>. doi: <pub-id pub-id-type="doi">10.1128/spectrum.03579-23</pub-id></citation>
</ref>
<ref id="ref22">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Muchaamba</surname> <given-names>F.</given-names></name> <name><surname>Stephan</surname> <given-names>R.</given-names></name></person-group> (<year>2024</year>). <article-title>A comprehensive methodology for microbial strain typing using Fourier-transform infrared spectroscopy</article-title>. <source>Methods Protoc.</source> <volume>7</volume>. doi: <pub-id pub-id-type="doi">10.3390/mps7030048</pub-id>, PMID: <pub-id pub-id-type="pmid">38921827</pub-id></citation>
</ref>
<ref id="ref23">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Novais</surname> <given-names>&#x00C2;.</given-names></name> <name><surname>Freitas</surname> <given-names>A. R.</given-names></name> <name><surname>Rodrigues</surname> <given-names>C.</given-names></name> <name><surname>Peixe</surname> <given-names>L.</given-names></name></person-group> (<year>2019</year>). <article-title>Fourier transform infrared spectroscopy: unlocking fundamentals and prospects for bacterial strain typing</article-title>. <source>Eur. J. Clin. Microbiol. Infect. Dis.</source> <volume>38</volume>, <fpage>427</fpage>&#x2013;<lpage>448</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10096-018-3431-3</pub-id></citation>
</ref>
<ref id="ref24">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Passaris</surname> <given-names>I.</given-names></name> <name><surname>Mauder</surname> <given-names>N.</given-names></name> <name><surname>Kostrzewa</surname> <given-names>M.</given-names></name> <name><surname>Burckhardt</surname> <given-names>I.</given-names></name></person-group> (<year>2022</year>). <article-title>Validation of Fourier transform infrared spectroscopy for serotyping of <italic>Streptococcus pneumoniae</italic></article-title>. <source>J. Clin. Microbiol.</source> <volume>60</volume>:<fpage>e0032522</fpage>. doi: <pub-id pub-id-type="doi">10.1128/jcm.00325-22</pub-id>, PMID: <pub-id pub-id-type="pmid">35699436</pub-id></citation>
</ref>
<ref id="ref25">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Paton</surname> <given-names>J. C.</given-names></name> <name><surname>Trappetti</surname> <given-names>C.</given-names></name></person-group> (<year>2019</year>). <article-title><italic>Streptococcus pneumoniae</italic> capsular polysaccharide</article-title>. <source>Gram Posit. Pathog.</source>, <fpage>304</fpage>&#x2013;<lpage>315</lpage>. doi: <pub-id pub-id-type="doi">10.1128/9781683670131.ch19</pub-id></citation>
</ref>
<ref id="ref26">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rappuoli</surname> <given-names>R.</given-names></name> <name><surname>De</surname> <given-names>G. E.</given-names></name> <name><surname>Costantino</surname> <given-names>P.</given-names></name> <name><surname>Smith</surname> <given-names>D.</given-names></name> <name><surname>Anderson</surname> <given-names>P.</given-names></name> <name><surname>Anderson</surname> <given-names>P.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>On the mechanisms of conjugate vaccines</article-title>. <source>PNAS</source> <volume>116</volume>, <fpage>14</fpage>&#x2013;<lpage>16</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.1819612116</pub-id></citation>
</ref>
<ref id="ref27">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Qian</surname> <given-names>D. Q.</given-names></name> <name><surname>Shi</surname> <given-names>W.</given-names></name> <name><surname>Yu</surname> <given-names>D.</given-names></name> <name><surname>Hu</surname> <given-names>Y. K.</given-names></name></person-group> (<year>2021</year>). <article-title>Epidemiology of non-vaccine serotypes of <italic>Streptococcus pneumoniae</italic> before and after universal administration of pneumococcal conjugate vaccines</article-title>. <source>Hum. Vaccin. Immunother.</source> <volume>17</volume>, <fpage>5628</fpage>&#x2013;<lpage>5637</lpage>. doi: <pub-id pub-id-type="doi">10.1080/21645515.2021.1985353</pub-id>, PMID: <pub-id pub-id-type="pmid">34726580</pub-id></citation>
</ref>
<ref id="ref28">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shoji</surname> <given-names>H.</given-names></name> <name><surname>V&#x00E1;zquez-S&#x00E1;nchez</surname> <given-names>D. A.</given-names></name> <name><surname>Gonzalez-Diaz</surname> <given-names>A.</given-names></name> <name><surname>Cubero</surname> <given-names>M.</given-names></name> <name><surname>Tubau</surname> <given-names>F.</given-names></name> <name><surname>Santos</surname> <given-names>S.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>Overview of pneumococcal serotypes and genotypes causing diseases in patients with chronic obstructive pulmonary disease in a Spanish hospital between 2013 and 2016</article-title>. <source>Infect. Drug Resist.</source> <volume>11</volume>, <fpage>1387</fpage>&#x2013;<lpage>1400</lpage>. doi: <pub-id pub-id-type="doi">10.2147/IDR.S165093</pub-id>, PMID: <pub-id pub-id-type="pmid">30214260</pub-id></citation>
</ref>
<ref id="ref29">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Silva-Costa</surname> <given-names>C.</given-names></name> <name><surname>Brito</surname> <given-names>M. J.</given-names></name> <name><surname>Pinho</surname> <given-names>M. D.</given-names></name> <name><surname>Fri&#x00E3;es</surname> <given-names>A.</given-names></name> <name><surname>Aguiar</surname> <given-names>S. I.</given-names></name> <name><surname>Ramirez</surname> <given-names>M.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>Pediatric complicated pneumonia caused by <italic>streptococcus pneumoniae</italic> serotype 3 in 13-valent pneumococcal conjugate vaccinees, Portugal, 2010&#x2013;2015</article-title>. <source>Emerg. Infect. Dis.</source> <volume>24</volume>, <fpage>1307</fpage>&#x2013;<lpage>1314</lpage>. doi: <pub-id pub-id-type="doi">10.3201/eid2407.180029</pub-id>, PMID: <pub-id pub-id-type="pmid">29912700</pub-id></citation>
</ref>
<ref id="ref30">
<citation citation-type="book"><person-group person-group-type="author">
<collab id="coll4">SIREVA</collab>
</person-group> (<year>2023</year>). <source>Secretaria de Estado da Sa&#x00FA;de. Coordenadoria de Controle de Doen&#x00E7;as Instituto Adolfo Lutz. Informa&#x00E7;&#x00E3;o da vigil&#x00E2;ncia das pneumonias e meningites bacterianas: Instituto Adolfo Lutz</source>. Available at: <ext-link xlink:href="http://www.ial.sp.gov.br/resources/insituto-adolfo-lutz/publicacoes/sireva_2023_2.pdf" ext-link-type="uri">http://www.ial.sp.gov.br/resources/insituto-adolfo-lutz/publicacoes/sireva_2023_2.pdf</ext-link> (Accessed November 13, 2024).</citation>
</ref>
<ref id="ref31">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Swarthout</surname> <given-names>T. D.</given-names></name> <name><surname>Gori</surname> <given-names>A.</given-names></name> <name><surname>Bar-Zeev</surname> <given-names>N.</given-names></name> <name><surname>Kamng&#x2019;ona</surname> <given-names>A. W.</given-names></name> <name><surname>Mwalukomo</surname> <given-names>T. S.</given-names></name> <name><surname>Bonomali</surname> <given-names>F.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>Evaluation of pneumococcal serotyping of nasopharyngeal-carriage isolates by latex agglutination, whole-genome sequencing (PneumoCaT), and DNA microarray in a high-pneumococcal-carriage-prevalence population in Malawi</article-title>. <source>J. Clin. Microbiol.</source> <volume>59</volume>, <volume>59</volume>:<fpage>e02103-20</fpage>. doi: <pub-id pub-id-type="doi">10.1128/JCM.02103-20</pub-id></citation>
</ref>
<ref id="ref32">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thadchanamoorthy</surname> <given-names>V.</given-names></name> <name><surname>Dayasiri</surname> <given-names>K.</given-names></name></person-group> (<year>2021</year>). <article-title>Review on pneumococcal infection in children</article-title>. <source>Cureus</source> <volume>13</volume>, <fpage>1</fpage>&#x2013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.7759/cureus.14913</pub-id></citation>
</ref>
<ref id="ref33">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Velusamy</surname> <given-names>S.</given-names></name> <name><surname>Tran</surname> <given-names>T.</given-names></name> <name><surname>Mongkolrattanothai</surname> <given-names>T.</given-names></name> <name><surname>Walker</surname> <given-names>H.</given-names></name> <name><surname>McGee</surname> <given-names>L.</given-names></name> <name><surname>Beall</surname> <given-names>B.</given-names></name></person-group> (<year>2020</year>). <article-title>Expanded sequential quadriplex real-time polymerase chain reaction (PCR) for identifying pneumococcal serotypes, penicillin susceptibility, and resistance markers</article-title>. <source>Diagn. Microbiol. Infect. Dis.</source> <volume>97</volume>:<fpage>115037</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.diagmicrobio.2020.115037</pub-id>, PMID: <pub-id pub-id-type="pmid">32265073</pub-id></citation>
</ref>
<ref id="ref34">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weiser</surname> <given-names>J. N.</given-names></name> <name><surname>Ferreira</surname> <given-names>D. M.</given-names></name> <name><surname>Paton</surname> <given-names>J. C.</given-names></name></person-group> (<year>2018</year>). <article-title><italic>Streptococcus pneumoniae</italic>: transmission, colonization and invasion</article-title>. <source>Nat. Rev. Microbiol.</source> <volume>16</volume>, <fpage>355</fpage>&#x2013;<lpage>367</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41579-018-0001-8</pub-id>, PMID: <pub-id pub-id-type="pmid">29599457</pub-id></citation>
</ref>
<ref id="ref35">
<citation citation-type="book"><person-group person-group-type="author">
<collab id="coll5">WHO</collab>
</person-group> (<year>2011</year>). <source><italic>Neisseria meningitidis</italic>, <italic>Streptococcus pneumoniae</italic>, diagnosis of meningitis caused by laboratory methods for the and <italic>Haemophilus influenzae</italic>: WHO manual</source>. <edition>2nd</edition> Edn: <publisher-name>World Health Organizarion</publisher-name>.</citation>
</ref>
<ref id="ref36">
<citation citation-type="other"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>Y.</given-names></name> <name><surname>Zhen</surname> <given-names>H. C.</given-names></name> <name><surname>Fang</surname> <given-names>C.</given-names></name> <name><surname>Ping</surname> <given-names>X. Y.</given-names></name> <name><surname>Li</surname> <given-names>W.</given-names></name> <name><surname>Fu</surname> <given-names>Y.</given-names></name></person-group> (<year>2021</year>). <article-title>Properties of mucoid serotype 3 <italic>Streptococcus pneumoniae</italic> from children in China</article-title> <volume>11</volume>, <fpage>1</fpage>&#x2013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.3389/fcimb.2021.648040</pub-id></citation>
</ref>
</ref-list>
</back>
</article>